Roche
Swiss multinational healthcare company that operates worldwide under two divisions: Pharmaceuticals and Diagnostics.
Launch date
Employees
Market cap
€176.5b
Enterprise valuation
€197.8b (Public information from Sep 2024)
Share price
CHF268.39999 ROG.SW
Company register number CHE-105.815.381
Basel Canton of Basel-Stadt (HQ)
Corporate Venture Fund: Roche Venture Fund
Financials
Estimates*
| CHF | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 58.3b | 62.8b | 63.3b | 60.4b | 60.8b | 64.2b | 66.8b |
| % growth | (5 %) | 8 % | 1 % | (4 %) | 1 % | 6 % | 4 % |
| EBITDA | 22.5b | 22.9b | 21.5b | 18.7b | 23.2b | 25.1b | 26.4b |
| % EBITDA margin | 39 % | 36 % | 34 % | 31 % | 38 % | 39 % | 40 % |
| Profit | 14.3b | 13.9b | 12.4b | 11.5b | 12.8b | 15.0b | 16.0b |
| % profit margin | 25 % | 22 % | 20 % | 19 % | 21 % | 23 % | 24 % |
| EV / revenue | 4.6x | 5.2x | 4.3x | 3.6x | 4.0x | 3.8x | 3.5x |
| EV / EBITDA | 11.8x | 14.2x | 12.8x | 11.6x | 10.6x | 9.6x | 8.9x |
| R&D budget | 13.0b | 14.8b | 16.0b | 14.2b | - | - | - |
| R&D % of revenue | 22 % | 24 % | 25 % | 23 % | - | - | - |
Source: Dealroom estimates
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
| N/A | N/A | IPO | |
| N/A | N/A | Post IPO Equity | |
| N/A | $6.5m | Debt | |
N/A | - | ||
$500k | Post IPO Equity | ||
$5.0b | Post IPO Equity | ||
* | N/A | $5.5b | Post IPO Debt |
| Total Funding | - | ||
Related Content
Recent News about Roche
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.
Investments analysisEdit
Investments by Roche
Edit
ACQUISITION by Roche Jun 2017
ACQUISITION by Roche Feb 2019
ACQUISITION by Roche Dec 2017
ACQUISITION by Roche Jan 2016
ACQUISITION by Roche Jul 2008
ACQUISITION by Roche Venture Fund Feb 2018
ACQUISITION by Roche Dec 2023
exited
ACQUISITION by Roche Jan 2015
ACQUISITION by Roche Aug 2014